ElixaCore, LLC a green pharmaceutical company announces it plans to produce safe, innovative therapeutic products to provide effective, natural, alternative medications and support patients with chronic and/or severe conditions.
With a management team possessing more than 95 years of professional, collective experience in industry related fields, this innovative company plans to use cutting-edge technology and research to serve potential patients, doctors, healthcare professionals and hospitals. ElixaCore and its board of advisors is committed to making the lives of consumers and clients better while offering groundbreaking brands that makes a positive difference in patient’s lives.
“We plan to be an active part of the future of medicine and how it effects patients and their families lives,” said Paul Tucker, Chief Executive Officer of ElixaCore. “The passion of our team and their personal life experiences drive us to research, discover and innovate new therapeutics that helps patients without giving them debilitating side effects,” he explained.
The ElixaCore executive team is a committed assembly of professionals with an important combination of talent, education, and skills and the company has the capacity of meeting its goals of servicing patients and communities.
“We have adopted a simply philosophy of patient care first, community, education and profitability’s for this who’s support green medicine initiatives,” asserted Tucker. “It is circle of healing that will allow ElixaCore to be inventive in the future of medicine while energizing the communities it serves.”
In April 2016, Pennsylvania (PA) has passed the Medical Marijuana Act to establish medical marijuana programs in PA. The act allows applicants to obtain certifications, licenses and permits for patients, caregivers, and for medical marijuana organizations.
Currently, Pennsylvania has approved 17 severe conditions that may use of medical marijuana as a treatment option. These conditions are Amyotrophic Lateral Sclerosis, Autism, Cancer, Crohn’s Disease, Damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, Epilepsy, Glaucoma, HIV (Human Immunodeficiency Virus) / AIDS (Acquired Immune Deficiency Syndrome), Huntington’s Disease, Inflammatory Bowel Syndrome, Intractable Seizures, Multiple Sclerosis, Neuropathies, Parkinson’s Disease, Post-traumatic Stress Disorder, Severe chronic or intractable pain of neuropathic origin or severe chronic or intractable pain in which conventional therapeutic intervention and opiate therapy is contraindicated or ineffective.
If approved, ElixaCore has plans to research, develop and distribute safe, therapeutic solutions in one or more of the aforementioned approved areas, operating within state and federal regulations.
“Green medicine is the future of therapeutics and all the infinite possibilities must be explored and we have the resources,” said Tucker. “In addition, the health, social, economical impact of medical marijuana in PA can not be ignored and all must understand its value.”
For more information about ElixaCore and it affiliates please visit www.elixacore.com or email us at firstname.lastname@example.org